Therapeutic use of a Fraximus augustifolia extract
AssigneeNaturex, S.A.
InventorsPascale Elizabeth Renée Fança-Berthon, Leila Denise Falcao, Antoine Charles Bily, Marc Roller, Simona Birtic
Life of this patent
Estimating the term…
Abstract
The present invention relates to extracts from Fraxinus angustifolia samara, processes for providing such extracts, and methods and uses of the extracts obtained. In particular, the present invention relates to the use of such extracts in reversing obesity-related and/or metabolic syndrome-related gut microbiota dysbiosis treatment, treating or preventing hepatic steatosis, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and modulating and/or adjusting gut microbiota.
Claims13
A method for:
- (a) reversing metabolic syndrome-related gut microbiota dysbiosis;
- (b) treating hepatic steatosis, non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH);
- (c) treating gut microbiota dysbiosis-induced cardiovascular diseases and/or cardiometabolic diseases;
- and/or
- (d) delaying the progression of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH);
- comprising the administration of a therapeutically effective amount of a Fraxinus angustifolia samara extract to a subject in need thereof, wherein the extract comprises:
- (i) from about 1% to about 16% by weight of nuzhenide;
- (ii) from about 1% to about 18% by weight of GL3;
- (iii) oleoside methyl ester;
- (iv) excelside B;
- (v) GL5;
- and
- (vi) salidroside.
A method of modulating or adjusting gut microbiota for treating non-alcoholic fatty liver disease (NAFLD) and/or delaying the progression of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) comprising the administration of an effective amount of a Fraxinus angustifolia samara extract to a subject in need thereof, wherein the extract comprises:
- (i) from about 1% to about 16% by weight of nuzhenide;
- (ii) from about 1% to about 18% by weight of GL3;
- (iii) oleoside methyl ester;
- (iv) excel side B;
- (v) GL5;
- and
- (vi) salidroside.
Dependencies are inferred from the claim text.